分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Inhibition of GSDMD Activates Poly(ADP-ribosyl)ation and Promotes Myocardial Ischemia-Reperfusion Injury

Zheng-hao Zhang, Zi-guan Zhang, Min-wei Chen, Ying Yang, Run-jing Li, Jia-jia Xu, Cui Yang, Yu-ying Li, Hong-wei Chen, Shi-xiao Liu, Yan-ling Li, Ping Luo, Yi-jiang Liu, Wen-bo Chen, Zhong-gui Shan,

Journal:Oxidative Medicine and Cellular Longevity

IF:7.31

DOI:10.1155/2022/1115749

PMID:35783187

Published:2022-06-24

research field:生物医学工程免疫学药学传染病学微生物学纳米医学

Abstract

The precise control of cardiomyocyte viability is imperative to combat myocardial ischemia-reperfusion injury (I/R), in which apoptosis and pyroptosis putatively contribute to the process. Recent researches indicated that GSDMD is involved in I/R as an executive protein of pyroptosis. However, its effect on other forms of cell death is unclear. We identified that GSDMD and GSDMD-N levels were significantly upregulated in the I/R myocardium of mice. Knockout of GSDMD conferred the resistance of the hearts to reperfusion injury in the acute phase of I/R but aggravated reperfusion injury in the chronic phase of I/R. Mechanistically, GSDMD deficiency induced the activation of PARylation and the consumption of NAD+ and ATP, leading to cardiomyocyte apoptosis. Moreover, PJ34, a putative PARP-1 inhibitor, reduced the myocardial injury caused by GSDMD deficiency. Our results reveal a novel action modality of GSDMD in the regulation of cardiomyocyte death; inhibition of GSDMD activates PARylation, suggesting the multidirectional role of GSDMD in I/R and providing a new theory for clinical treatment.

本文使用的Yeasen产品

购物车
客服
转染试用